// App-Quantinova.ai

: High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Researchers

Presenter

  • Yago Nieto

Principal Investigators

  • Peter F Thall

  • Jeremy L. Ramdial

  • Samer A Srour

  • Chitra Hosing

  • Neeraj Saini

  • Amin M Alousi

  • Muzaffar H Qazilbash

  • Uday R Popat

  • Alison Gulbis

  • Terri Lynn Shigle

  • Roland Bassett

  • Maria Guillermo-Pacheco

  • Celina Ledesma

  • Paolo Strati

  • Sairah Ahmed

  • Raphael Steiner

  • Jason Westin

  • Ranjit Nair

  • Swaminathan P. Iyer

  • Richard E Champlin

  • Elizabeth J Shpall

  • Borje S Andersson

Medical Centers

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Autoimmune (AI)

  • Genetic Disorder

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Infectious Diseases (ID)

  • Urology

Disease

  • Hyperbilirubinemia

  • Prostate cancer

  • T-cell lymphoma

  • Gynaecological cancer

  • Breast cancer

  • Solid malignancies

  • Arrhythmia

  • Lymphomas

  • Mucositis

  • Ulcerative colitis

  • Sepsis

  • Diffuse large B-cell lymphoma

Biomarkers

  • B-lymphocyte antigen CD20

  • Apparent diffusion coefficient

Drug/Treatment

  • Gemcitabine

  • Vorinostat

  • Melphalan

  • Rituximab

  • Busulfan

  • Olaparib

  • ribose

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved